ContraFect (CFRX) Receives $2.1M PRMRP-Related Development Award
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
ContraFect Corporation (Nasdaq: CFRX) (Nasdaq: CFRXW) announced that it has been granted a $2.1 million Technology/Therapeutic Development Award through the US Department of Defense Peer Reviewed Medical Research Program (PRMRP).
The Technology/Therapeutic Development Award is designed to support diagnostics or therapies that have the potential to make a strong impact on patient care. The award is granted after a peer-review process and will support the development of ContraFect's principal therapeutic candidate, CF-301, a first-in-class lysin which is active against Staphylococcus aureus (Staph aureus) bacteria.
"We are pleased to receive this award which will support additional research on CF-301 for the current development program in Staph aureus bacteremia and endocarditis, as well as potential future indications," said Steven C. Gilman, PhD, Chairman and CEO of ContraFect.
CF-301 is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staph aureus bacteremia. It has a novel, rapid, and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm infections. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect. CF-301 is the first lysin to enter clinical trials in the U.S.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Whirlpool (WHR) Announces U.S. Confirms Samsung and LG Dumped Washers
- Flowers Foods (FLO) and Flowers Baking Reach Settlement in Class Action Lawsuit
- Basic Energy Services (BAS) Announces Court Approval Of Restructuring and Recap Plan
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!